Treatment of N2 non-small cell lung cancer (NSCLC).

1 Arriagada R, Bertino JR, Bleehen NM, Brodin 0, Feld B, Goldie JH, Hansen HH, et al and the Workshop participants. Consensus report on combined radiotherapy and chemotherapy modalities in lung cancer. In: Arriagada R, Le Chevalier T, eds. Treatnsent modalities in lung cancer. Basel: Karger, 1988; vol 41, 232-4 1 2 S#{248}rensen JB, Hansen HH. Review of nsethodological problems in the interpretation of phase II trials in nonsnsall-cell lung cancer. In: Arriagada R, Le ChevalierT, eds. Treatment modalities in lung cancer. Basel: Karger, 1988; vol 41, 57-64 3 B#{233}nichouJ, Chastang C. Use of triangular test in the analysis of randomized clinical trials when the response criterion is censored: Application to two trials in lung cancer. In: Arriagada R, Le Chevalier T, eds. Treatment modalities in lung cancer. Basel: Karger, 1988; vol 41, 83-91 4 Payne DC, Feld R. Concurrent radiotherapy and chemotherapy in lung cancer at the Princess Margaret Hospital. In: Arriagada R, Le Chevalier T, eds. Treatment modalities in long cancer. Basel: Karger, 1988; vol 41, 96-101 5 Kaasa S, Olsnes BT, Thorud E, H#{216}st H. Reduced short-term neuropsychological performance in patients with nonsmall-cell lung cancer treated with cisplatin and etoposide. In: Arriagada R, Le Chevalier T, eds. Treatment modalities in lung cancer. Basel: Karger, 1988; vol 41 226-31